Achaogen Inc

Achaogen — Investor Presentation (January 2018)

37 slides from Achaogen's investor presentation, Jan 11, 2018

  1. Slide 1: Corporate Presentation

    Corporate Presentation Nasdaq: AKAO January 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospective products, p

  3. Slide 3: Achaogen: Innovative Products for Serious Infections

    Achaogen: Innovative Products for Serious Infections Large and growing patient populations Strong physician interest Value-based pricing potential Significant Commercial Opportunity Committed to addressing the urgent threat posed by multi-drug resistant (MDR) bacterial infections Pipeline of innovat

  4. Slide 4: Multi-Drug Resistance Poses an Urgent and Growing Threat

    Multi-Drug Resistance Poses an Urgent and Growing Threat Resistance rising rapidly2 High morbidity and mortality (up to 50% in BSI due to CRE)1,3 Limited treatment options4 Significant economic burden to healthcare system & society5 © Achaogen, Inc. All rights reserved. CDC Urgent1 CDC Serious1 Prio

  5. Slide 5: There is a Demand for New Therapies to Fight MDR Infections

    There is a Demand for New Therapies to Fight MDR Infections © Achaogen, Inc. All rights reserved. 1Diagn Microbiol Infect Dis 2016, http://dx.doi.org/10.1016/j.diagmicrobio.2016.04.022 E.coli is the causative pathogen in 79% of complicated UTI (incl. pyelonephritis): Lancet 2015;385:1949. 2.Source:

  6. Slide 6: Pipeline to Address the Serious Threat of Antibiotic Resistance

    CRE: carbapenem-resistant Enterobacteriaceae MDR: multi-drug resistant Pipeline to Address the Serious Threat of Antibiotic Resistance Program Preclinical Phase 1 Phase 2 Phase 3 Registration All product candidates are investigational only, potential treatments, and have not been approved for commer

  7. Slide 7: Plazomicin has Potent Activity Against MDR Enterobacteriaceae

    Plazomicin has Potent Activity Against MDR Enterobacteriaceae, Including ESBL-Producers, CRE Strains and AG-Resistant Isolates Plazomicin: A Next Generation Aminoglycoside for the Potential Treatment of MDR Enterobacteriaceae Discovered at Achaogen; US patent protection currently estimated 2030-2032

  8. Slide 8: Plazomicin Results Demonstrate Unique Clinical Profile

    Plazomicin Results Demonstrate Unique Clinical Profile Reported positive results in two Phase 3 clinical trials, NDA submitted Phase 3 registration trial (vs. meropenem) 609 patients enrolled Achieved FDA and EMA-specified primary efficacy endpoints Lower relapse rate at Late Follow-Up in plazomicin

  9. Slide 9: Positive Efficacy Results in EPIC Phase 3 Trial in cUTI/AP

    Positive Efficacy Results in EPIC Phase 3 Trial in cUTI/AP Plazomicin demonstrated non-inferiority on FDA endpoint and statistical superiority to meropenem on EMA endpoints * lower bound of the CI exceeds zero indicating statistical superiority TOC: Test-of-Cure visit Composite Cure includes microbi

  10. Slide 10: EPIC Efficacy Results

    © Achaogen, Inc. All rights reserved. * Lower bound of the CI exceeds zero. Microbiological eradication defined as baseline uropathogen reduced to <104 CFU/mL. TOC, test of cure 15-19 days from 1st dose IV study drug; LFU, late follow-up 24-32 days from 1st dose IV study drug. Clinical Relapse at LF

  11. Slide 11: EPIC Overall Summary of TEAEs and SAEs

    EPIC Overall Summary of TEAEs and SAEs Similar incidence across study arms Most common TEAEs occurring in plazomicin-treated patients were diarrhea (2.3%), hypertension (2.3%), headache (1.3%), nausea (1.3%) and vomiting (1.3%) One death in the plazomicin group due to pre-existing cancer, not relate

  12. Slide 12: CARE Primary Efficacy Results

    CARE Primary Efficacy Results Improved outcomes at Day 28 for plazomicin treated patients versus colistin Difference [Colistin minus Plazomicin] (90% CI) Results: Lower values are better © Achaogen, Inc. All rights reserved. 26.5% (-0.7, 51.2%) 28.2% (0.7, 52.5%) 23.5% 11.8% Day 28 all-cause mortali

  13. Slide 13: CARE Efficacy Results: BSI

    CARE Efficacy Results: BSI Reduced mortality at Day 28 for plazomicin versus colistin in BSI Two-sided 90% CI calculated based on the unconditional exact method. Plazomicin Colistin 2/14 8/15 1/14 6/15 39.0% (9.4 to 65.5) 32.9% (4.0 to 60.1) BSI Subset (mMITT Population) Difference (colistin minus p

  14. Slide 14: CARE Kaplan-Meier Survival Curve

    Censored + + CARE Kaplan-Meier Survival Curve Sustained survival benefit in plazomicin-treated patients with BSI Estimate of hazard ratio (HR) calculated as plazomicin:colistin based on Cox proportional hazards regression model. 0 20 40 60 80 100 Days 0 10 20 30 40 50 60 + + HR for death (plazomicin

  15. Slide 15: CARE Overall Summary of TEAEs and SAEs

    CARE Overall Summary of TEAEs and SAEs Favorable safety profile for plazomicin versus colistin Reduced drug-related AEs, SAEs, and AEs related to renal function in plazomicin arm No study drug-related deaths or events of ototoxicity reported © Achaogen, Inc. All rights reserved. Safety Population Pl

  16. Slide 16: CARE Laboratory Parameters Associated with Renal Function

    CARE Laboratory Parameters Associated with Renal Function Notable reduction in serum creatinine elevations in plazomicin arm Serum Creatinine (Safety Population)1 Plazomicin (N = 18) n/N1 (%) Colistin (N = 21) n/N1 (%) ≥0.5 mg/dL increase any time on study (including on or post IV therapy) 2/12 (16.

  17. Slide 17: Plazomicin Commercial Opportunity and Launch Readiness

    Plazomicin Commercial Opportunity and Launch Readiness © Achaogen, Inc. All rights reserved.

  18. Slide 18: Strength of Phase 3 Data and Favorable Administration Profile

    Statistically superior to meropenem at TOC Once daily 30-min IV Product Profile Opportunity ESBL+ cUTI Carbapenem sparing opportunity Sub-populations at highest risk CRE Out-Patient cUTI Patient discharge reduces costs Improved survival vs. colistin at Day 28 Improved safety vs. colistin © Achaogen,

  19. Slide 19: Plazomicin is Uniquely Positioned to Succeed in CRE and High-Risk cUTI Markets

    Plazomicin is Uniquely Positioned to Succeed in CRE and High-Risk cUTI Markets Compelling Phase 3 Data – Survival benefit in CRE, sustained efficacy in cUTI Potential Label – NDA includes potential indications in both cUTI and BSI Differentiated Class – Only aminoglycoside amongst new market entrant

  20. Slide 20: Estimated 1.5 Million Days of Potential Opportunity for Plazomicin in CRE

    Estimated 1.5 Million Days of Potential Opportunity for Plazomicin in CRE Infections in the US & EU5 in 2016 Confirmed CRE Opportunity X ~180 K CRE Cases = ~2% Confirmed CRE Sources: Decision Resources, Arlington Medical Resources, primary literature, CDC & ECDC, TSN Surveillance Network, TEST Surve

  21. Slide 21: Significant Growth in Confirmed CRE Cases in the U.S.

    Significant Growth in Confirmed CRE Cases in the U.S. with Approximately 70K to 80K Cases in 2016 and Trending Upwards Sources: Literature-based projection: Literature review combined with surveillance network data EHR-based projection: Analysis of Cerner Health Facts EHR database from ~200 hospital

  22. Slide 22: Opportunity can be Captured With Efficient Commercial Model

    Opportunity can be Captured With Efficient Commercial Model Given Concentration of CRE Source: IMS DDD, 2015-2016; IMS HCOS 2016 1 meropenem, imipenem and doripenem 2 Avycaz & Colistin Use Widespread Carbapenem Use1 Concentrated Use of CRE Drugs2 © Achaogen, Inc. All rights reserved. Achaogen Needs

  23. Slide 23: Plazomicin Launch Preparations Well Underway

    Plazomicin Launch Preparations Well Underway Sales force sizing and territory mapping complete VP of Sales and front-line sales management hired Medical Science field team fully staffed and in field Advisory boards and KOL roundtables conducted Cross-functional team engaged in launch planning Launch

  24. Slide 24: Plazomicin Potential Approval and Launch Dates in 2018 Remain Base Case

    Plazomicin Potential Approval and Launch Dates in 2018 Remain Base Case Plazomicin Drug Product Regulatory Overview Assumed facility for plazomicin launch continues to be Pfizer-McPherson © Achaogen, Inc. All rights reserved. Form 483 is a form used by the FDA to document and communicate concerns di

  25. Slide 25: C-Scape: Oral Antibiotic Candidate for cUTI

    C-Scape: Oral Antibiotic Candidate for cUTI © Achaogen, Inc. All rights reserved.

  26. Slide 26: C-Scape Executive Summary

    C-Scape Executive Summary Oral antibiotic to treat infections due to ESBL-producing Enterobacteriaceae WHO: Critical Priority 1 Pathogen CDC: Serious Public Health Threat Higher probability of clinical and regulatory success given history of use of individual components Compelling commercial opportu

  27. Slide 27: New Oral Antibiotics are Needed to Treat cUTI and AP due to ESBL-Producing Enterobacteriaceae

    New Oral Antibiotics are Needed to Treat cUTI and AP due to ESBL-Producing Enterobacteriaceae Fluoroquinolones (85% Non-susceptible)* Amoxicillin-Clavulanate (56% Non-susceptible)* Cephalosporins† (55% Non-susceptible)* Trimethoprim-Sulfamethoxazole (70% Non-susceptible)* *Source: MIC testing of 379

  28. Slide 28: C-Scape is a Uniquely Potent β-lactam / β-lactamase Inhibitor Combination

    Organism ESBL Enzyme Amoxicillin-Clavulanate MIC (µg/mL) Ciprofloxacin MIC (µg/mL) C-Scape MIC (µg/mL) E. coli CTX-M-15,TEM-1 16 ≤0.03 0.5 E. coli CTX-M-15,TEM-1 8 >4 0.5 E. coli CTX-M-14 8 ≤0.03 0.5 K. pneumoniae SHV-5,TEM-1 8 0.25 0.12 K. pneumoniae SHV WT,CTX-M-15, OXA-1/30-like 16 1 0.5 K. pneum

  29. Slide 29: C-Scape Shows Potency Against ESBL-Producing Enterobacteriaceae

    C-Scape Shows Potency Against ESBL-Producing Enterobacteriaceae Cumulative Percent of Isolates MIC (μg/mL) C-Scape MIC90 = 1 μg/mL in ESBL-Producing Enterobacteriaceae 379 E. coli or K. pneumoniae from US & EU (2014-15) genotyped for CTX-M, TEM or SHV ESBLs 10 5 0 Time (h) LOD 024624 C-Scape is Rapi

  30. Slide 30: Clavulanate Restores the Efficacy of Ceftibuten Against Target Pathogens

    Clavulanate Restores the Efficacy of Ceftibuten Against Target Pathogens © Achaogen, Inc. All rights reserved. hours 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 Vehicle Ceftibuten Ceftibuten+Clavulanate Ceftibuten Ceftibuten+Clavulanate Vehicle Log10 CFU Change Log10 CFU 24 Hours ESBL-Producing E. coli

  31. Slide 31: C-Scape Phase 1 Top-Line Results

    C-Scape Phase 1 Top-Line Results The combination of ceftibuten/clavulanate was well tolerated when administered for 14 days across all dosing regimens tested No serious adverse events (SAEs), grade 3 or 4 adverse events, or adverse events leading to discontinuation of study drug were observed Safety

  32. Slide 32: C-Scape Addresses a Large and Growing Patient Population

    C-Scape Addresses a Large and Growing Patient Population With Strong Physician Interest in Product Profile Sources: Decision Resources, Arlington Medical Resources, primary literature, CDC, TSN Surveillance Network, TEST Surveillance Database, and company internal analysis NVC Consulting Qual/Quant

  33. Slide 33: Potential for Two Complementary Gram-Negative Antibiotics in Our Sales Force

    Potential for Two Complementary Gram-Negative Antibiotics in Our Sales Force Expand Hospital Footprint with Potential Launch of C-Scape Establish Hospital Team of ~65 with Potential Launch of Plazomicin Plazomicin C-Scape © Achaogen, Inc. All rights reserved.

  34. Slide 34: Corporate Profile

    Corporate Profile © Achaogen, Inc. All rights reserved.

  35. Slide 35: Financial Snapshot

    Financial Snapshot $199.4 million in cash, cash equivalents, short-term investments at 9/30/17 Additional restricted cash of $10.7 million associated with Gates Foundation partnership at 9/30/17 Funding partnerships BARDA non-dilutive funding of $124.3 million for plazomicin development BARDA non-di

  36. Slide 36: Significant Progress & Strong Execution

    2017 2018 ü Significant Progress & Strong Execution Multiple Drug Candidates to to Address Significant Patient Need ü Plazomicin NDA submission C-Scape Ph 1 results Advance C-Scape to Ph 3 Plazomicin commercial launch Plazomicin FDA action June 25 Plazomicin MAA submission ü Plazomicin NDA accepted

  37. Slide 37: Achaogen - Thank you

    _ ACHAOGEN a. Thank you

Achaogen — Investor Presentation (January 2018) on 6ix